Blog

  • GSK Delivers Strong Q1 Performance and Advances R&D Pipeline

    GSK Delivers Strong Q1 Performance and Advances R&D Pipeline

    GSK plc (LSE:GSK) began 2026 with solid momentum, reporting first-quarter sales of £7.6 billion, up 5% at constant exchange rates. Growth was driven by a 14% increase in Specialty Medicines, with strong double-digit gains in HIV, respiratory, and oncology treatments. Vaccines recorded modest growth, while general medicines declined. Core operating profit rose 10% and core earnings per share increased 9%, supported by a more favorable product mix, disciplined cost management, and higher royalty income.

    The company generated £0.8 billion in free cash flow during the quarter, enabling continued share buybacks and a 17p dividend. Management reaffirmed its full-year 2026 guidance, targeting low- to mid-single-digit revenue growth alongside high-single-digit expansion in core profit and earnings.

    GSK also highlighted accelerating progress across its research and development pipeline. The quarter included new approvals for treatments in asthma, COPD, and multiple myeloma, as well as global regulatory filings for hepatitis B candidate bepirovirsen. The company reported breakthrough and PRIME designations for its liver disease therapy efimosfermin and outlined plans for several pivotal trial readouts and oncology studies throughout 2026. These efforts are complemented by targeted acquisitions in areas such as food allergy and pulmonary hypertension.

    In addition, GSK confirmed that its 2026 outlook incorporates a new agreement with the U.S. government, which trades lower prescription drug prices for relief from potential Section 232 tariffs on patented pharmaceuticals through early 2029. This arrangement reduces a key policy risk for its U.S. business and provides greater visibility for investors.

    Overall, the company’s outlook is supported by strong profitability, improving fundamentals, and continued pipeline progress. Valuation appears reasonable, with a modest dividend yield, though some caution remains due to technical indicators suggesting overbought conditions and ongoing considerations around balance sheet strength and earnings consistency.

    More about GlaxoSmithKline

    GSK plc is a global biopharmaceutical company focused on developing and commercialising specialty medicines, vaccines, and general pharmaceuticals. It holds strong positions in key therapeutic areas including respiratory, HIV, oncology, and vaccines such as shingles and meningitis. The company aims to drive growth through higher-margin specialty products while managing a more mature general medicines portfolio across major global markets.

  • Sylvania Platinum Delivers Strong Q3 Results on Higher PGM Prices and Chrome Output

    Sylvania Platinum Delivers Strong Q3 Results on Higher PGM Prices and Chrome Output

    Sylvania Platinum Limited (LSE:SLP) reported solid third-quarter results for the period to 31 March 2026, supported by stronger commodity pricing and rising chrome production. Its dump operations produced 22,853 ounces of 4E platinum group metals, slightly lower due to seasonal factors but still ahead of internal expectations. Meanwhile, chrome output from the Thaba joint venture surged 80% to 19,030 tons.

    Improved PGM basket prices and increased chrome sales drove a 44% rise in net revenue to $78.7 million, while adjusted EBITDA climbed 61% to $47.8 million. The company’s cash position strengthened by 17% to $63.3 million, enabling continued shareholder returns through a buyback programme and interim dividend. However, full-year 2026 chrome production guidance has been reduced בעקבות feed quality issues and weather-related disruptions, while PGM output is still expected to reach or exceed the upper end of the 90,000 to 93,000 ounce target range.

    Looking ahead, Sylvania’s outlook is supported by improving operational fundamentals and a strong, low-leverage balance sheet. However, negative free cash flow remains a constraint. From a market perspective, technical indicators suggest mixed momentum, with some near-term weakness balanced by longer-term trend support. Valuation appears moderate, with a modest dividend yield providing some underpinning.

    More about Sylvania Platinum

    Sylvania Platinum Limited is a platinum group metals producer focused on South Africa and listed on AIM. The company operates six Sylvania Dump Operations plants that recover PGMs from chrome tailings, making it a leading producer in the tailings retreatment segment. It also has exposure to chrome production and holds interests in mining rights and a joint venture at Thaba, supporting its growth in both PGM and chrome markets.

  • Arrow Exploration Reports Production Growth and Strong Reserves While Funding Expansion from Cash

    Arrow Exploration Reports Production Growth and Strong Reserves While Funding Expansion from Cash

    Arrow Exploration Corp. (LSE:AXL) reported 2025 net income of $1.4 million on oil and gas revenue of $70.5 million, alongside adjusted EBITDA of $35 million. Average production increased 13% to 4,012 barrels of oil equivalent per day, despite a weaker commodity price environment. During the year, the company drilled 14 development wells and one successful exploration well in Colombia, while maintaining a solid financial position with $11 million in cash and no debt. Operations were completed without any safety or environmental incidents.

    The company also published its year-end reserves update, reporting 11,775 thousand barrels of oil equivalent in proved plus probable reserves, with a pre-tax net present value of $245 million. This highlights the long-term potential of its Colombian asset base. For 2026, Arrow has outlined a fully funded $24 million work programme, targeting up to nine new wells on the Tapir block. The company expects to finance its capital spending through operating cash flow and existing cash reserves, while also working toward securing an extension of its key Tapir block contract, which remains central to its growth plans.

    More about Arrow Exploration Corp

    Arrow Exploration Corp. is a Canada-based oil and gas producer headquartered in Calgary, focused on high-growth operations in Colombia, complemented by natural gas assets in Alberta. Its core strategy centres on developing and expanding production from the Tapir block, including fields such as Rio Cravo Este, Carrizales Norte, Alberta Llanos, and Mateguafa. The company aims to increase output and cash generation while maintaining a debt-free balance sheet.

  • ZOO Digital Meets FY26 Targets as Cost Savings and Fast Track Service Support Outlook

    ZOO Digital Meets FY26 Targets as Cost Savings and Fast Track Service Support Outlook

    ZOO Digital Group plc (LSE:ZOO) reported preliminary results for the year to 31 March 2026 in line with expectations, forecasting at least $3.8 million in adjusted EBITDA on revenue of $42.3 million. The performance follows a cost restructuring programme that delivered $7.3 million in savings. The company ended the period with $3.2 million in cash and $1.1 million drawn on invoice financing facilities, which were expanded in the U.S. to $5 million alongside a £2 million UK facility to support working capital as revenues grow.

    Management noted that the media and entertainment landscape in FY26 was shaped by evolving content strategies, including a shift toward licensed content and increased demand for live and near-live programming such as sports and episodic formats. These trends contributed to new client onboarding following recent tender wins. ZOO also highlighted rising demand for its Fast Track localisation service, designed to deliver complex multi-language projects quickly through technology-enabled workflows. In addition, the company signalled governance changes, including a board refresh, the appointment of new independent directors, and a planned transition at chair level.

    Despite these developments, the company’s outlook remains cautious. Financial performance continues to reflect ongoing losses and weaker free cash flow, while technical indicators point to a bearish trend, with the share price trading below key moving averages. However, recent results provide some positive signals through cost reductions, improving margins, and positive cash EBITDA. These gains are partly offset by declining revenues and reduced cash levels.

    More about Zoo Digital

    ZOO Digital Group plc is a technology-driven localisation and digital media services company serving the global entertainment industry. It partners with major Hollywood studios and leading streaming platforms, using proprietary technology and a network of more than 12,000 freelancers to provide services including dubbing, subtitling, captioning, metadata, mastering, artwork, and media processing. The company enables content owners to distribute films, series, and live events across multiple languages, regions, and formats.

  • Sanderson Design Group Improves Profitability and Cash Position on Efficiency Gains

    Sanderson Design Group Improves Profitability and Cash Position on Efficiency Gains

    Sanderson Design Group plc (LSE:SDG) reported revenue of £99.5 million for the year to 31 January 2026, broadly unchanged year on year, while delivering a significant improvement in profitability. Adjusted underlying profit before tax rose 22.2% to £5.3 million, and the group returned to a statutory pre-tax profit of £3.1 million. Net cash increased to £9.8 million, and the company maintained its dividend, supported by tighter cost control and operational efficiencies.

    The group highlighted strong growth in licensing income and a recovery in manufacturing profitability. Performance in North America was particularly robust, with brand revenues exceeding £22 million. Digital initiatives also gained traction, with all brands now supported by direct-to-consumer platforms and increasing online sales. Management continues to prioritise expansion in the U.S. market and improvements in manufacturing efficiency, even as conditions in the UK remain subdued and geopolitical uncertainty persists.

    Despite these operational gains, the broader outlook remains constrained by weaker financial trends, including prior losses, soft revenue performance, and negative operating and free cash flow. Technical indicators offer some support, with the share price showing strong momentum and trading above key moving averages, though overbought signals suggest potential volatility. Valuation remains mixed, with a modest dividend yield offset by a negative price-to-earnings ratio linked to recent losses.

    More about Sanderson Design Group PLC

    Sanderson Design Group plc is a UK-based designer, manufacturer, and distributor of premium interior furnishings, including wallpapers, fabrics, and paints. The company also licenses its designs for products such as bedding, rugs, and tableware. Its portfolio includes heritage brands such as Zoffany, Sanderson, Morris & Co., Harlequin, Clarke & Clarke, and Scion, supported by UK manufacturing sites and showrooms in London, New York, and Chicago.

  • Watkin Jones Maintains Profit Levels as Revenue Falls and Pipeline Builds for Second Half

    Watkin Jones Maintains Profit Levels as Revenue Falls and Pipeline Builds for Second Half

    Watkin Jones plc (LSE:WJG) reported steady profitability for the half year to 31 March 2026, despite a decline in revenue linked to lower transactional activity. The company said operating profit is expected to be broadly in line with the previous year, supported by solid execution across its in-build developments, which delivered margins in line with guidance.

    During the period, Watkin Jones secured two new projects, including a purpose-built student accommodation scheme in Bristol and a hotel development in Wimbledon. Its broader development pipeline remained stable, underpinned by a 20% increase in opportunities within its Development Partnerships segment. The group also maintained a strong cash position while continuing to manage cost pressures and adjust its pipeline in response to uncertainty סביב UK interest rates and market liquidity.

    Management highlighted disciplined cash management, with gross cash of حوالي £67 million and net cash of roughly £61 million at the end of the period. Although slightly lower than the previous financial year, this level of liquidity remains supportive of ongoing developments. Looking ahead, the company aims to drive stronger performance in the second half by progressing scheme sales, diversifying income streams, and taking proactive steps to control construction cost inflation amid shifting economic and geopolitical conditions.

    However, the outlook remains challenging. Watkin Jones continues to face pressure from declining revenues, reduced profitability, and tighter liquidity conditions. Technical indicators also suggest a negative trend in the share price, adding further caution to the investment case.

    More about Watkin Jones

    Watkin Jones plc is a leading UK developer and manager of residential-for-rent properties, with a strong focus on purpose-built student accommodation and the wider living sector. The company operates across development, asset management, and partnership models, primarily serving institutional investors and residential investment markets across the UK.

  • Serica Energy Secures $300m Bond Financing to Strengthen Liquidity

    Serica Energy Secures $300m Bond Financing to Strengthen Liquidity

    Serica Energy plc (LSE:SQZ) has successfully raised $300 million through a new issue of five-year senior unsecured Nordic bonds, with the offering significantly oversubscribed. The bonds carry an annual coupon of 7.875% and attracted strong interest from investors across the Nordic region, the UK, and international markets. Settlement is expected around 12 May 2026, with plans to list the bonds on the Euronext ABM market in Oslo.

    The company intends to use the net proceeds to fully repay its drawn Reserve Based Lending (RBL) facility, while retaining the structure for future flexibility. This move is expected to lift pro forma liquidity to approximately $675 million. Management said the transaction enhances balance sheet strength, broadens funding sources, and positions Serica to pursue growth opportunities, including acquisitions and development projects across its North Sea portfolio.

    Serica’s outlook reflects a mixed financial picture. Recent performance has been weaker, with a decline in 2025 revenue, a reported net loss, and negative free cash flow. However, these factors are partly offset by strong share price momentum and a supportive earnings outlook, including reaffirmed 2026 guidance, an improving net debt position, and a maintained dividend. Valuation is underpinned by an attractive yield, though the negative price-to-earnings ratio highlights ongoing profitability challenges.

    More about Serica Energy

    Serica Energy plc is an independent UK oil and gas company focused on the UK Continental Shelf, where it accounts for roughly 10% of domestic gas production. Its key producing assets include the Bruce, Keith, and Rhum fields in the Northern North Sea, as well as interests in fields linked to the Triton FPSO in the Central North Sea. The company also holds a 40% operated stake in the Greater Laggan Area and the Shetland Gas Plant.

    Serica is pursuing further growth through acquisitions, including planned stakes in the Catcher and Golden Eagle fields from ONE-Dyas and additional assets from Spirit Energy expected in 2026. Currently listed on AIM under ticker SQZ, the company intends to transition to the London Stock Exchange Main Market as part of its longer-term strategy to expand scale and enhance shareholder value.

  • AstraZeneca Reports Robust Q1 Growth and Advances High-Value Drug Pipeline

    AstraZeneca Reports Robust Q1 Growth and Advances High-Value Drug Pipeline

    AstraZeneca plc (LSE:AZN) delivered a strong start to 2026, posting first-quarter total revenue of $15.3 billion, an 8% increase at constant exchange rates. Growth was led by double-digit gains in oncology and rare diseases, helping drive a 12% rise in core operating profit and a 5% increase in core earnings per share. Management reiterated its full-year outlook, expecting mid-to-high single-digit revenue growth and low double-digit core EPS expansion, supported by a projected 21% core tax rate and improving margins.

    The quarter also featured significant progress in the company’s late-stage pipeline. Positive Phase III trial results were reported for tozorakimab in chronic obstructive pulmonary disease and efzimfotase alfa in hypophosphatasia. AstraZeneca also secured 14 regulatory approvals across major markets and submitted several new applications, highlighting continued momentum in bringing new therapies to market.

    Strategic partnerships further strengthened its long-term growth profile. These included a $1.2 billion upfront collaboration with CSPC Pharmaceutical Group focused on obesity and type 2 diabetes, as well as licensing agreements with Jacobio Pharmaceuticals and Pinetree Therapeutics. These initiatives reflect AstraZeneca’s push into next-generation oncology treatments and metabolic therapies, supporting its ambitions through to 2030.

    Overall, the company’s outlook is underpinned by strong operational performance and a positive earnings trajectory, reinforced by pipeline advancements and strategic deals. However, valuation remains relatively elevated, with a price-to-earnings ratio around 30, while free cash flow has shown some variability. Technical indicators also suggest the stock may be somewhat overextended despite maintaining a broader upward trend.

    More about AstraZeneca

    AstraZeneca plc is a global biopharmaceutical company focused on the development and commercialization of prescription medicines. Its core therapeutic areas include oncology, rare diseases, cardiovascular, renal and metabolic conditions, as well as respiratory and immunology. The company emphasizes innovation through both internal research and strategic collaborations, particularly in advanced areas such as antibody-drug conjugates and next-generation metabolic treatments.

  • Melrose Delivers Strong Q1 Profit Growth and Maintains 2026 Outlook

    Melrose Delivers Strong Q1 Profit Growth and Maintains 2026 Outlook

    Melrose Industries plc (LSE:MRO) reported an 11% increase in first-quarter revenue, supported by robust performance across its key divisions. The Engines business led the way with 20% growth, while Airframes posted a 4% rise, driving adjusted operating profit for both segments and the overall group well above the prior year.

    The Engines division benefited from strong deliveries of newer original equipment as well as broad-based aftermarket expansion, particularly in repair activity and military programmes. In Airframes, defence-related demand grew at a double-digit pace, complemented by modest gains in civil aviation. However, lower narrowbody volumes reflected softer conditions across parts of the commercial aerospace market.

    Melrose said net debt and free cash flow remained in line with expectations. While the company has limited direct exposure to the Middle East, it highlighted some indirect risks, including rising freight costs and uncertainty around civil aviation activity due to the ongoing conflict. Despite these factors, management reaffirmed its full-year 2026 guidance, projecting revenue between £3.75 billion and £3.95 billion, adjusted operating profit of £700 million to £750 million, and free cash flow in the range of £150 million to £200 million. The outlook reflects confidence in stronger second-half performance and continued growth momentum into 2026 and beyond.

    Overall, the company’s prospects are supported by improving operational fundamentals and clear, growth-oriented guidance, including expectations for margin expansion and higher cash generation. However, some challenges remain, particularly around uneven cash conversion and elevated leverage. Technical indicators also weigh on sentiment, with the stock trading below key moving averages, while valuation appears broadly balanced, offering only limited support from dividend yield.

    More about Melrose

    Melrose Industries plc is a global aerospace and defence company specialising in aircraft engines and airframe systems. It supplies both original equipment and aftermarket services, leveraging proprietary technologies and established positions on major commercial and military aircraft platforms. The group focuses on markets with strong long-term growth potential and resilient demand characteristics.

  • Jubilee Metals Secures Court Backing for Capital Reduction Plan

    Jubilee Metals Secures Court Backing for Capital Reduction Plan

    Jubilee Metals Group (LSE:JLP) has received approval from the High Court of Justice to proceed with a reduction of its share premium account, marking an important legal step in its broader capital restructuring efforts. The change will become effective once the court order and revised statement of capital are formally registered with the Registrar of Companies, enabling the company to gain greater flexibility over future capital allocation and potential shareholder distributions.

    This court-approved move aligns with Jubilee’s wider strategy to strengthen its financial structure as it works toward developing an integrated copper operation in Zambia. By optimising its balance sheet, the company aims to improve its ability to fund expansion projects and support shareholder-focused initiatives, reinforcing its platform for long-term growth in copper production.

    Despite this strategic progress, the company’s near-term outlook remains weighed down by a sharp decline in recent financial performance, including significant drops in revenue and profitability alongside negative free cash flow. Some support comes from management actions to reduce risk, including asset disposals and operational improvements in Zambia. However, uncertainty persists due to deferred guidance and ongoing operational and financing challenges. Market signals remain mixed to weak, with technical indicators pointing to negative momentum and valuation constrained by continued losses.

    More about Jubilee Metals Group

    Jubilee Metals Group is a metals processing company listed on AIM in London and on the AltX of the Johannesburg Stock Exchange. It is focused on building a fully integrated copper business in Zambia, targeting annual production of around 25,000 tonnes. The group combines exploration, mining, processing, and refining through assets such as the Roan concentrator, Sable refinery, regional mining operations, and its Large Waste Rock Project, while emphasising innovative technologies and circular resource practices.